houghtalingbaemo1268.blogspot.com
The Department of Health’s proposed regulations relatee to marketing activities by pharmaceutica and medical device manufacturerss will create an unquestionably restrictive environment forthese However, the administration wisely opted to excludee from the requirements disclosure of legitimate paymentss related to clinical trials. A vocalo minority has since raiseda stink, suggesting that the statew health officials caved to This is ridiculous.
The administration has simplu done the right Recent data from showed thatin biopharmaceutical-related companies were responsible for almost 55,000 jobs in the The university’s also projected that 15,000o new jobs in the biopharmaceutical industru will be generated in Massachusetts by 2014. Lawmakersz showed great determination and vision in championing the recentlty enacted lifesciences initiative. These effortsx could have been jeopardized if not for the actiones of the Departmentof Health.
Our state officials took crucial step to ensure that ongoinbg clinical research conducted in partnership betweenh local physiciansand scientists, academic medical centers and life sciences companies is not threatened by overly restrictived disclosure requirements. It is the right decisionh for thepublic health, for this unique and dynamixc life sciences sector, and for the near-term prospects of our localo economy.
Kelly Thompson Clark Presidentand CEO,
No comments:
Post a Comment